BIOGEN

Cognition impairment is common in MS, affecting 40-70% of individuals, and can have a negative impact on Quality of Life (QoL).1 The National MS Society recommends an early baseline screening with the SDMT or similarly validated tests (e.g. the Processing Speed Test in CogEval) for people diagnosed with MS.2... CogEval is an iPad-based assessment designed to evaluate cognitive function in patients with Multiple Sclerosis (MS). Based on the Symbol Digital Modalities Test (SMDT), CogEval assess elements of attention, psychomotor speed, visual processing, and working memory.

Also known as: Biogen Inc.